Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Pfizer

Overview

RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Conditions

RSV Infection Stem Cell Transplant Complications Lower Resp Tract Infection

Interventions

RV521 oral tabletDRUG

Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

Placebo oral tabletDRUG

Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Has undergone autologous or allogeneic HCT using any conditioning regimen within 1 year of randomization. Subjects who have undergone HCT more than 1 year before Randomization are eligible if all other inclusion/exclusion criteria are satisfied and under at least one of the following conditions: 1. Diagnosed with Chronic Graft-vs-Host Disease (GVHD), or 2. Has used systemic corticosteroids in the 30 days prior to RSV infection 2. Has moderate to severe immunocompromise, defined as a score ≥ 5 on the ISI-RSV and/or an ALC of ≤ 500 cells/ mm3 3. Documentation of positive RSV infection in the upper airway Exclusion Criteria: 1. Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT. 2. Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization. 3. Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible. 4. Known chronic infection with hepatitis B, C, or HIV. 5. Is in the pre-engraftment period during RSV infection. 6. Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator. 7. Any condition requiring mechanical ventilation or vasopressor support at the time of randomization. 8. Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated. 9. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated. 10. Excessive nausea/vomiting at Screening or an inability to swallow capsules. 11. Elevation of hepatic enzymes or renal compromise.

Outcomes

Primary Outcomes

Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study

Progression to LRTC during the study defined as one of the following: * Primary LRTI caused by RSV * Secondary bacterial LRTI * LRTI caused by another pathogen * LRTC of unknown etiology

Time frame: Pre-dose baseline (Day 1) through Visit 8 (Day 28)

Change in RSV nasal viral load (via RT-qPCR)

RSV change measured by the time-weighted average (DAVG) viral load using RT qPCR

Time frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)

Secondary Outcomes

Percent of participants who experience AEs, TEAEs, SAEs and withdrawals due to TEAEs

Safety analyses will include a summary of AEs, including but not limited to n (%) of subjects in each treatment group and overall.

Time frame: First dose of study drug through Visit 8 (Day 28)

Evaluate safety and tolerability of RV521 by assessing changes from baseline in systolic and diastolic BP (vital sign parameters)

BP will be collected in mm Hg. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.

Time frame: Baseline through Visit 8 (Day 28)

Evaluate safety and tolerability of RV521 by assessing changes from baseline in body temperature (vital sign parameters)

Body Temperature will be collected in degrees Fahrenheit (°F) or degrees Celsius (°C). Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.

Time frame: Baseline through Visit 8 (Day 28)

Evaluate safety and tolerability of RV521 by assessing changes from baseline in respiration rate (vital sign parameters)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Respiration rate will be measured in breaths per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.

Time frame: Baseline through Visit 8 (Day 28)

Evaluate safety and tolerability of RV521 by assessing changes from baseline in pulse/heart rate (vital sign parameters)

Heart rate will be measured in beats per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.

Time frame: Baseline through Visit 8 (Day 28)

Evaluate safety and tolerability of RV521 by assessing changes from baseline weight/BMI

Weight and height will be collected and combined to report BMI

Time frame: Baseline through Visit 8 (Day 28)

Evaluate the proportion of subjects with changes and shifts in hematology/clinical chemistry/urinalysis laboratory values (laboratory tests read by a central lab) from baseline.

Results at each visit will be summarized using the statistics n, mean, standard deviation, median, minimum and maximum. Also, change from baseline will also be summarized by post baseline visits.

Time frame: Collected at Visit 2/Day 1 (pre-dose), Visit 4/Day 3, Visit 6/Day 14 and Visit 8/Day 28

Evaluate the proportion of subjects with changes in ECG measurements and changes in clinical impression from baseline

ECGs will be taken with a centrally supplied ECG machine and electronically transmitted to a central ECG repository. ECG will only be evaluated by the Investigator for normal, abnormal NCS and abnormal CS. Parameters collected will be: * Ventricular Heart Rate (bpm) * PR Interval (msec) * QRS Interval (msec) * QT Interval (msec) * QTcB Interval (msec) Results at each visit will be summarized using the statistics: n (number of observations), mean, SD, median, minimum and maximum.

Time frame: Measurements will be taken at Day 1/Visit 2 (pre-dose and at 5-hours post-dose), on Day 3/Visit 4 (at 5 hours post-dose), and at Visit 6 (Day 14)

Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by RT-qPCR

Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by RT-qPCR.

Time frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)

Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by CBIA

Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by CBIA.

Time frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)

Mean change in RSV viral load assessed via CBIA

change measured by the time weighted average (DAVG) viral load using CBIA

Time frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)

Mean change from baseline in viral RNA shedding

RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.

Time frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)

Proportion of subjects who no longer shed RSV assessed by both RT-qPCR and CBIA at each timepoint

RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.

Time frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)

Time to improvement in RSV-related symptoms

Defined as all symptoms present at initiation of therapy are mild or no longer present. (absent/resolved)

Time frame: Daily from baseline (Day 1) through Visit 8 (Day 28)

Time to total resolution of all RSV-related symptoms

Defined as all symptoms are no longer present.

Time frame: Daily from baseline (Day 1) through Visit 8 (Day 28)

Proportion of days with lowest daily SpO2 ≥ 90% on room air

SpO2 measured at every visit. For subjects on oxygen or who are mechanically ventilated may have this waived.

Time frame: Daily from baseline (Day 1) through Visit 8 (Day 28)

Number of days where supplementary oxygen was required

Use of daily supplementary oxygen will be collected throughout the study.